TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

April 18, 2024

https://www.globenewswire.com/news-release/2024/04/18/2865236/8790/en/TG-Therapeutics-Awarded-National-Contract-by-the-Department-of-Veterans-Affairs-for-BRIUMVI-as-the-Preferred-Anti-CD20-for-Relapsing-Forms-of-Multiple-Sclerosis.html

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.